Close

Anti-CD22 (Bectumomab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 (XS-0323-ZP16)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The integration of synthetic antigen receptors into immune cells has emerged as a potent approach for treating various diseases, particularly through the use of T cells engineered to express chimeric antigen receptors (CAR) for targeted cancer therapy. However, in addition to T lymphocytes, B lymphocytes also hold great potential as immune cells that can be genetically modified for therapeutic purposes, such as the production of recombinant antibodies or protein replacement therapy. To this end, CAR-B cells are a promising avenue for achieving localized delivery of monoclonal antibodies to tumor sites by targeting specific tumor-associated antigens (TAA).

Creative Biolabs has developed an innovative design for a new class of synthetic antigen receptors, known as chimeric B cell receptors (CBCR). The Anti-CD22 (Bectumomab) h(scFv-CD28TM-CD79β) CBCR(CAR-B) vector is composed of an anti-CD22 antibody-based binding domain, which is fused with the CD79β signaling domain, a component of the B cell receptor (BCR) complex that is responsible for activation. This vector can be introduced into primary murine B cells, resulting in high levels of surface expression and antigen recognition, independent of the endogenous BCR.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD22
  • Targeting Cell Type
  • T cell
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD28TM-CD79β

Target

  • Clone
  • Bectumomab
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD22
  • Synonyms
  • CD22;CD22; CD22 Molecule; CD22 Molecule; CD22 Antigen; Sialic Acid-Binding Ig-Like Lectin 2; B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD22 (Bectumomab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 (XS-0323-ZP16). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.